Digest Network Come funziona
Network
/
Società
Co
Non verificato

Coya Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

59 comunicati stampa

Guarda tutti i comunicati
08/09/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
11/08/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Salute
Medicina - Varie
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
18/06/2026
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
15/06/2026
Web e Social Network
Scienza
Sport
Medicina - Varie
Calcio
Biotecnologia
Salute
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
08/06/2026
Industria
Scienza
Medicina - Varie
Biologia
Biotecnologia
Sanità
Salute
Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
27/05/2026
Biotecnologia
Sanità
Salute
Farmaceutica
Eventi
Industria
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
12/05/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Farmaceutica
Sanità
Salute
Igiene alimentare
Psichiatria
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
12/05/2026
Industria
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
09/04/2026
Industria
Biotecnologia
Igiene alimentare
Salute
Sanità
Farmaceutica
Scienza
Psichiatria
Medicina - Varie
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
02/04/2026
Mercato del lavoro
Sanità
Scienza
Farmaceutica
Medicina - Varie
Biotecnologia
Igiene alimentare
Salute
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0